Session » (0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I
-
Abstract Number: 0544
Autoantibodies to dsDNA and Associated Proteins: Association with Proteinuria and Lupus Nephritis
-
Abstract Number: 0545
Referral Pattern and Factors Associated with Time to Diagnosis for Lupus in India- multicentric Data from the SLE Special Interest Group (SIG) of the Indian Rheumatology Association (IRA)
-
Abstract Number: 0546
Markers of Oxidative Stress in Systemic Lupus Erythematosus Patients with Nephritis
-
Abstract Number: 0547
A Spatially-resolved Single Cell Resolution Atlas of Pediatric Lupus Nephritis Uncovers Complex Interactions Between Stromal and Infiltrating Immune Cells
-
Abstract Number: 0548
Clinical and Interferon Biomarkers to Exclude Imminent Autoimmune Disease in ANA Positive Individuals
-
Abstract Number: 0549
Development of Customized Digital Cognitive Assessment Battery: A Pilot Use Case in SLE Patients
-
Abstract Number: 0550
Harnessing Machine Learning to Predict Neuropsychiatric Events in Systemic Lupus Erythematosus
-
Abstract Number: 0551
Monogenic Lupus: Clinical Phenotypes and Genetic Mutations in a Cohort of Pediatric Patients
-
Abstract Number: 0552
The Impact of Antiphospholipid Antibodies on Future Atherosclerotic Cardiovascular Disease Risk in Systemic Lupus Erythematosus
-
Abstract Number: 0553
Serum Isolevuglandin IgG Antibody Concentrations Are Increased in Patients with Systemic Lupus Erythematosus versus Control Subjects and Associated with Lower 24-hour Blood Pressure
-
Abstract Number: 0554
A Refined Disease Activity Immune Index Informed by Select Immune Mediators That Characterizes Clinical Disease Activity in Systemic Lupus Erythematosus
-
Abstract Number: 0555
Evaluation and Management of the “False Positive” ANA and Undifferentiated Connective Tissue Disease Amongst Rheumatologists
-
Abstract Number: 0556
Classical Complement Activation in Lupus Nephritis Correlates with Disease Biomarkers: Results from Two Observational Studies
-
Abstract Number: 0557
Longitudinal Evaluation of Cell-bound Complement Activation Products in Patients with SLE
-
Abstract Number: 0558
Elevated Serum Levels of S100A8/A9 Discriminate Systemic Lupus Erythematosus Patients with Cognitive Impairment from Patients Without Impairment
-
Abstract Number: 0559
Development of Charlson Comorbidity Index (CCI) Comorbidities and CCI Score in Danish Nationwide Cohort of 3,178 Patients with Newly Diagnosed Systemic Lupus Erythematosus
-
Abstract Number: 0560
Genetic Determinants of Lupus Nephritis and Kidney Function in Systemic Lupus Erythematosus
-
Abstract Number: 0561
Frequency of Anti-Ro Antibodies in Systemic Lupus Erythematosus Patients: Insights from Multicenter and National Registry
-
Abstract Number: 0562
HDL-Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus
-
Abstract Number: 0563
Urinary Neutrophil Gelatinase-associated Lipocalin (NGAL) as a Mediator of the Association Between Particulate Matter Exposure and Disease Activity in Systemic Lupus Erythematosus
-
Abstract Number: 0564
Risk Factors for Immune Thrombocytopenia in Systemic Lupus Erythematosus and Generation of a Predictive Model to Assess Its Risk of Development
-
Abstract Number: 0565
Insulin Resistance and the Complement System Are Linked in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 0566
Characterization of Disease Activity Using a Novel Physiologic Biomarker in Pediatric SLE
-
Abstract Number: 0567
N-Terminal Pro-Brain Natriuretic Peptide Correlates Strongly with Cardiovascular Damage in Systemic Lupus Erythematous (SLE): A Cross-sectional Study
-
Abstract Number: 0568
Comparison of Plasma Protein Profiles and Endothelial Function in Patients with Pediatric-Onset Systemic Lupus Erythematosus and Healthy Controls
-
Abstract Number: 0569
Serum S100A8 and S100A9 Are Useful Biomarker Indicated IFN Associated Organ Involvements in Systemic Lupus Erythematosus
-
Abstract Number: 0570
BLyS Levels Are Elevated in Systemic Lupus Erythematosus Patients with Neuropsychiatric Manifestations
-
Abstract Number: 0571
A Polygenic Risk Score for Systemic Lupus Erythematosus (SLE) Discriminates Between Patients with Lupus and Individuals Without Lupus and a Positive Antinuclear Antibody Test
-
Abstract Number: 0572
Serum/ Urine Levels and Expression of CD163 in Lupus Nephritis
-
Abstract Number: 0573
Presence of Mediterranean Fever Gene Variants Provides Protection from the Development of Lupus Nephritis in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 0574
Type I IFN-associated Regulation of Immune Checkpoint Genes in Patients with SLE
-
Abstract Number: 0575
The Real-World Utility of a Lupus Activity Monitoring Panel in the United States Community Rheumatologist Practice
-
Abstract Number: 0576
Enhancing Systemic Lupus Erythematosus Diagnosis: Comparative Performance Characteristics of TC4d and Anti-T-Cell Antibodies with Conventional Biomarkers
-
Abstract Number: 0577
Analysis of Intracytoplasmic Toll – Like Receptors (TLRs) and MyD88 Expression in B Cell Subsets in Patients with Lupus Nephritis
-
Abstract Number: 0578
Prospective Observational Study of Microvascular C5b-9 Deposition in Non-lesional Skin in Systemic Lupus Erythematosus Patients and Its Correlation with Active Lupus Nephritis
-
Abstract Number: 0579
Sub-types of Ischemic Stroke in Systemic Lupus Erythematosus,-associations with STAT4 and HLA-DRB1 Risk Genotypes